Companies: 10,795·Total market cap: $144.5T
Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNMAMEXHealthcare● Active
$1.06
$-0.02(-1.85%)
Market Cap$33257494
P/E Ratio
52W High$1.945
52W Low$0.952
SEC Filings

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001388320 · ATNM · AMEX · as of Jun 9, 2026

Filing snapshot

494
Total Filings
8-K
Latest Form
2026-05-29
Most Recent
2012
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001388320 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-30
Fiscal Year End
Mar 30, 2026
Accession No.
0001213900-26-036504
Primary Document
ea0279291-10k_actinium.htm
Source: data.sec.gov · CIK 0001388320 · Accession 0001213900-26-036504

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-08
8-KCurrent Report
CURRENT REPORT
2026-05-29Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
CURRENT REPORT
2026-05-29
View
10-QQuarterly Report
QUARTERLY REPORT
2026-05-08
View
10-KAnnual Report
ANNUAL REPORT
2026-03-30
View
8-K/ACurrent Report (Amended)
AMENDMENT NO.1 TO FORM 8-K
2026-03-26
View
8-KCurrent Report
CURRENT REPORT
2026-02-13
View
8-KCurrent Report
CURRENT REPORT
2025-11-26
View
10-QQuarterly Report
QUARTERLY REPORT
2025-11-14
View
ARSARS
ARS
2025-11-05
View
DEF 14AProxy Statement
PROXY STATEMENT
2025-11-05
View
10-QQuarterly Report
QUARTERLY REPORT
2025-08-08
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-07-29
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-07-16
View
10-QQuarterly Report
QUARTERLY REPORT
2025-05-09
View
8-KCurrent Report
CURRENT REPORT
2025-05-09
View
10-KAnnual Report
ANNUAL REPORT
2025-03-31
View
Showing 1–15 of 379 filingsForm 4 / 144 hidden· 494 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001388320  |  Exchange: AMEX · Healthcare

Actinium Pharmaceuticals, Inc. (AMEX: ATNM) has submitted 494 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2012. As a Healthcare sector company with CIK 0001388320, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Actinium Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Actinium Pharmaceuticals, Inc. 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical ATNM 10-K annual reports are available from 2007 through 2026.

Investors researching Actinium Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ATNM SEC Filings · 8 questions

Actinium Pharmaceuticals, Inc. (ATNM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 494 filings and access original documents at no cost. Actinium Pharmaceuticals, Inc.'s CIK is 0001388320.

ATNM SEC filingsActinium Pharmaceuticals, Inc. SEC documentsfind ATNM 10-K